OA12968A - Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof. - Google Patents

Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof. Download PDF

Info

Publication number: OA12968A
Authority: OA; OAPI
Prior art keywords: sait; fumarate; disease; disorder; solution
Prior art date: 2002-12-06

Application number

OA1200500173A

Other languages

English (en)

Inventor

Jon Gordon Selbo

Bradley Dee Hewitt

David Warner Rappath

Donn Gregory Wishka

Ahmad Yahya Sheikh

Original Assignee

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-06

Filing date

2003-12-01

Publication date

2006-10-13

2003-12-01 Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

2006-10-13 Publication of OA12968A publication Critical patent/OA12968A/en

Links

VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title claims abstract description 93
239000000203 mixture Chemical class 0.000 title claims abstract description 48
238000002360 preparation method Methods 0.000 title abstract description 3
ZFCRPEXKMXOUQT-UHFFFAOYSA-N furo[2,3-c]pyridine-2-carboxamide Chemical class C1=NC=C2OC(C(=O)N)=CC2=C1 ZFCRPEXKMXOUQT-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
201000010099 disease Diseases 0.000 claims abstract description 34
239000003814 drug Substances 0.000 claims description 61
229940079593 drug Drugs 0.000 claims description 58
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 53
150000001875 compounds Chemical class 0.000 claims description 40
239000013078 crystal Substances 0.000 claims description 34
208000024891 symptom Diseases 0.000 claims description 33
239000012458 free base Substances 0.000 claims description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
239000001530 fumaric acid Substances 0.000 claims description 27
239000000164 antipsychotic agent Substances 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
208000024827 Alzheimer disease Diseases 0.000 claims description 17
201000000980 schizophrenia Diseases 0.000 claims description 17
208000035475 disorder Diseases 0.000 claims description 16
238000010438 heat treatment Methods 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
230000001149 cognitive effect Effects 0.000 claims description 14
208000019901 Anxiety disease Diseases 0.000 claims description 13
238000000634 powder X-ray diffraction Methods 0.000 claims description 13
208000019022 Mood disease Diseases 0.000 claims description 12
208000028017 Psychotic disease Diseases 0.000 claims description 12
208000010412 Glaucoma Diseases 0.000 claims description 11
208000002193 Pain Diseases 0.000 claims description 11
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 10
208000010877 cognitive disease Diseases 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
206010064930 age-related macular degeneration Diseases 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 8
IQQNMLSLUVURHZ-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1OC=C2 IQQNMLSLUVURHZ-UHFFFAOYSA-N 0.000 claims description 8
208000002780 macular degeneration Diseases 0.000 claims description 8
208000023105 Huntington disease Diseases 0.000 claims description 7
230000003542 behavioural effect Effects 0.000 claims description 7
208000027061 mild cognitive impairment Diseases 0.000 claims description 7
230000004770 neurodegeneration Effects 0.000 claims description 7
208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
201000010374 Down Syndrome Diseases 0.000 claims description 6
201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
206010039966 Senile dementia Diseases 0.000 claims description 6
206010044688 Trisomy 21 Diseases 0.000 claims description 6
208000000103 Anorexia Nervosa Diseases 0.000 claims description 5
208000003174 Brain Neoplasms Diseases 0.000 claims description 5
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
206010036631 Presenile dementia Diseases 0.000 claims description 5
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 5
208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
208000030963 borderline personality disease Diseases 0.000 claims description 5
230000037406 food intake Effects 0.000 claims description 5
235000012631 food intake Nutrition 0.000 claims description 5
210000004558 lewy body Anatomy 0.000 claims description 5
230000036651 mood Effects 0.000 claims description 5
230000009529 traumatic brain injury Effects 0.000 claims description 5
238000005406 washing Methods 0.000 claims description 5
206010065040 AIDS dementia complex Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
208000034189 Sclerosis Diseases 0.000 claims description 4
208000000323 Tourette Syndrome Diseases 0.000 claims description 4
238000002441 X-ray diffraction Methods 0.000 claims description 4
208000013403 hyperactivity Diseases 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
230000001376 precipitating effect Effects 0.000 claims description 4
230000005586 smoking cessation Effects 0.000 claims description 3
108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 abstract description 31
102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 abstract description 30
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
IPKZCLGGYKRDES-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)furo[2,3-c]pyridine-5-carboxamide Chemical class C1N(CC2)CCC2C1NC(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-UHFFFAOYSA-N 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
239000000243 solution Substances 0.000 description 51
239000007787 solid Substances 0.000 description 50
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 44
230000000694 effects Effects 0.000 description 42
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
229940050411 fumarate Drugs 0.000 description 34
238000000034 method Methods 0.000 description 34
235000011087 fumaric acid Nutrition 0.000 description 26
229960002598 fumaric acid Drugs 0.000 description 25
238000006243 chemical reaction Methods 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
230000003935 attention Effects 0.000 description 20
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 19
238000011282 treatment Methods 0.000 description 19
235000019439 ethyl acetate Nutrition 0.000 description 16
238000012546 transfer Methods 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
239000000463 material Substances 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 11
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
229960002715 nicotine Drugs 0.000 description 11
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 11
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
238000003756 stirring Methods 0.000 description 11
102100024954 5-hydroxytryptamine receptor 3A Human genes 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
101150045775 Htr3a gene Proteins 0.000 description 9
230000036506 anxiety Effects 0.000 description 9
235000019441 ethanol Nutrition 0.000 description 9
239000012044 organic layer Substances 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000556 agonist Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
239000008177 pharmaceutical agent Substances 0.000 description 8
239000002002 slurry Substances 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
-1 NYL CARBOXAMIDE Chemical class 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
238000001179 sorption measurement Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000003693 atypical antipsychotic agent Substances 0.000 description 6
229940127236 atypical antipsychotics Drugs 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000000561 anti-psychotic effect Effects 0.000 description 5
230000019771 cognition Effects 0.000 description 5
231100000870 cognitive problem Toxicity 0.000 description 5
239000013058 crude material Substances 0.000 description 5
239000011549 crystallization solution Substances 0.000 description 5
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
108091006146 Channels Proteins 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 4
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
206010013663 drug dependence Diseases 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000015654 memory Effects 0.000 description 4
XLTANAWLDBYGFU-VTLKBQQISA-N methyllycaconitine Chemical compound C([C@]12CN([C@@H]3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-VTLKBQQISA-N 0.000 description 4
FRZAEBZEHFXWKR-UHFFFAOYSA-N methyllycaconitine Natural products CCN1CC2(COC(=O)c3ccccc3N4C(=O)CC(C)C4=O)CCC(O)C56C7CC8C(O)C7C(O)(CC8OC)C(O)(C(OC)C25)C16 FRZAEBZEHFXWKR-UHFFFAOYSA-N 0.000 description 4
XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 4
230000002085 persistent effect Effects 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
235000015320 potassium carbonate Nutrition 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010001540 Akathisia Diseases 0.000 description 3
206010002027 Amyotrophy Diseases 0.000 description 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 3
229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
206010012239 Delusion Diseases 0.000 description 3
206010067889 Dementia with Lewy bodies Diseases 0.000 description 3
208000012661 Dyskinesia Diseases 0.000 description 3
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 3
208000004547 Hallucinations Diseases 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
201000002832 Lewy body dementia Diseases 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
IPKZCLGGYKRDES-ZDUSSCGKSA-N Pha-543613 Chemical class N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-ZDUSSCGKSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000001431 Psychomotor Agitation Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
206010044565 Tremor Diseases 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229940005529 antipsychotics Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
231100000871 behavioral problem Toxicity 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 3
230000001713 cholinergic effect Effects 0.000 description 3
229960004170 clozapine Drugs 0.000 description 3
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
238000009225 cognitive behavioral therapy Methods 0.000 description 3
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
231100000868 delusion Toxicity 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
238000010265 fast atom bombardment Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
238000002825 functional assay Methods 0.000 description 3
BEVAEUJOJMQCIU-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OC=C2 BEVAEUJOJMQCIU-UHFFFAOYSA-N 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000010410 layer Substances 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000001144 powder X-ray diffraction data Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
230000009151 sensory gating Effects 0.000 description 3
239000000779 smoke Substances 0.000 description 3
230000000391 smoking effect Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
208000011117 substance-related disease Diseases 0.000 description 3
238000012360 testing method Methods 0.000 description 3
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
QZHXIGDVIINLKX-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)-4-iodopyridin-3-ol Chemical compound OCC1=CC(I)=C(O)C(Cl)=N1 QZHXIGDVIINLKX-UHFFFAOYSA-N 0.000 description 2
201000010000 Agranulocytosis Diseases 0.000 description 2
241000271566 Aves Species 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
208000028698 Cognitive impairment Diseases 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
239000007821 HATU Substances 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000015592 Involuntary movements Diseases 0.000 description 2
206010025421 Macule Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 2
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
208000021017 Weight Gain Diseases 0.000 description 2
208000000208 Wet Macular Degeneration Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
VCFCKAMFEDBLEX-UHFFFAOYSA-N butyl furo[2,3-c]pyridine-5-carboxylate Chemical compound C1=NC(C(=O)OCCCC)=CC2=C1OC=C2 VCFCKAMFEDBLEX-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229940112822 chewing gum Drugs 0.000 description 2
235000015218 chewing gum Nutrition 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
235000019504 cigarettes Nutrition 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
239000002178 crystalline material Substances 0.000 description 2
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000003596 drug target Substances 0.000 description 2
208000011325 dry age related macular degeneration Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
210000002816 gill Anatomy 0.000 description 2
208000035474 group of disease Diseases 0.000 description 2
229960003878 haloperidol Drugs 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960000423 loxapine Drugs 0.000 description 2
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
229960000300 mesoridazine Drugs 0.000 description 2
229960001344 methylphenidate Drugs 0.000 description 2
229960004938 molindone Drugs 0.000 description 2
239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
239000000181 nicotinic agonist Substances 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
229960005343 ondansetron Drugs 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
229960003634 pimozide Drugs 0.000 description 2
235000015497 potassium bicarbonate Nutrition 0.000 description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
239000011736 potassium bicarbonate Substances 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
230000001755 vocal effect Effects 0.000 description 2
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
229940018503 zyban Drugs 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
REUAXQZIRFXQML-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@@H](N)CN1CC2 REUAXQZIRFXQML-ZETCQYMHSA-N 0.000 description 1
STZHBULOYDCZET-KLXURFKVSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 1
JYTYBRREMOCQHE-UHFFFAOYSA-N (7-chlorofuro[2,3-c]pyridin-5-yl)methanol Chemical compound ClC1=NC(CO)=CC2=C1OC=C2 JYTYBRREMOCQHE-UHFFFAOYSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
RSOPTYAZDFSMTN-UHFFFAOYSA-N 2-chloropyridin-3-ol Chemical compound OC1=CC=CN=C1Cl RSOPTYAZDFSMTN-UHFFFAOYSA-N 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
101710138027 5-hydroxytryptamine receptor 3A Proteins 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
241000283707 Capra Species 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010010964 Coprolalia Diseases 0.000 description 1
RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001539473 Euphoria Species 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000011714 Glycine Receptors Human genes 0.000 description 1
108010076533 Glycine Receptors Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
206010027951 Mood swings Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
101000761345 Mus musculus 5-hydroxytryptamine receptor 3A Proteins 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
208000002033 Myoclonus Diseases 0.000 description 1
208000018526 Narcotic-Related disease Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000013200 Stress disease Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000008234 Tics Diseases 0.000 description 1
102000017434 Torsin Human genes 0.000 description 1
108050005633 Torsin Proteins 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
108020000715 acetylcholine receptors Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
230000037007 arousal Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
229950009852 carfenazine Drugs 0.000 description 1
TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
108700010039 chimeric receptor Proteins 0.000 description 1
229960001552 chlorprothixene Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
229960003120 clonazepam Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
229960000632 dexamfetamine Drugs 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
231100000318 excitotoxic Toxicity 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
UUKNFBHTKFKPEH-UHFFFAOYSA-N furo[2,3-c]pyridin-5-ylmethanol Chemical compound C1=NC(CO)=CC2=C1OC=C2 UUKNFBHTKFKPEH-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000009224 group psychotherapy Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940095895 haldol Drugs 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
231100000206 health hazard Toxicity 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000010365 information processing Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
101150010139 inip gene Proteins 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
240000004308 marijuana Species 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000004630 mental health Effects 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000007510 mood change Effects 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000010004 neural pathway Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960000761 pemoline Drugs 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
206010036067 polydipsia Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000012545 processing Methods 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
229960003598 promazine Drugs 0.000 description 1
239000003196 psychodysleptic agent Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
229940106887 risperdal Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000021317 sensory perception Effects 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000003461 thalamocortical effect Effects 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
229960005013 tiotixene Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000004515 ventral tegmental area Anatomy 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
229960000607 ziprasidone Drugs 0.000 description 1
229940039925 zyprexa Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200500173A 2002-12-06 2003-12-01 Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof. OA12968A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US43161902P	2002-12-06	2002-12-06

Publications (1)

Publication Number	Publication Date
OA12968A true OA12968A (en)	2006-10-13

Family

ID=32507764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500173A OA12968A (en)	2002-12-06	2003-12-01	Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof.

Country Status (22)

Country	Link
US (1)	US20050165047A1 (is)
EP (1)	EP1572700A1 (is)
JP (1)	JP2006510664A (is)
KR (1)	KR20050087826A (is)
CN (1)	CN1720248A (is)
AR (1)	AR042295A1 (is)
AU (1)	AU2003302911A1 (is)
BR (1)	BR0317019A (is)
CA (1)	CA2506529A1 (is)
CR (1)	CR7859A (is)
EA (1)	EA200500738A1 (is)
EC (1)	ECSP055834A (is)
HR (1)	HRP20050494A2 (is)
IS (1)	IS7844A (is)
MA (1)	MA27604A1 (is)
MX (1)	MXPA05005943A (is)
NO (1)	NO20052560L (is)
OA (1)	OA12968A (is)
PL (1)	PL377052A1 (is)
TW (1)	TW200427691A (is)
WO (1)	WO2004052894A1 (is)
ZA (1)	ZA200503988B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6670178B1 (en)	1992-07-10	2003-12-30	Transkaryotic Therapies, Inc.	In Vivo production and delivery of insulinotropin for gene therapy
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
US7094572B2 (en)	2003-03-14	2006-08-22	Bristol-Myers Squibb	Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
EP2254598B1 (en) *	2008-02-13	2013-07-10	Targacept, Inc.	Combination of alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI519532B (zh)	2010-05-17	2016-02-01	艾維沃製藥公司	（Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru)	2012-05-08	2019-02-08	Форум Фармасьютикалз, Инк.	Способы поддержания, лечения или улучшения когнитивной функции

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988002751A1 (fr) *	1986-10-13	1988-04-21	Asahi Kasei Kogyo Kabushiki Kaisha	Derives de pyridine
AR036040A1 (es) *	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen

2003
- 2003-12-01 JP JP2004558940A patent/JP2006510664A/ja active Pending
- 2003-12-01 BR BR0317019-5A patent/BR0317019A/pt unknown
- 2003-12-01 WO PCT/IB2003/005607 patent/WO2004052894A1/en not_active Ceased
- 2003-12-01 PL PL377052A patent/PL377052A1/pl not_active Application Discontinuation
- 2003-12-01 EP EP03812627A patent/EP1572700A1/en not_active Withdrawn
- 2003-12-01 AU AU2003302911A patent/AU2003302911A1/en not_active Abandoned
- 2003-12-01 KR KR1020057010196A patent/KR20050087826A/ko not_active Ceased
- 2003-12-01 MX MXPA05005943A patent/MXPA05005943A/es not_active Application Discontinuation
- 2003-12-01 CA CA002506529A patent/CA2506529A1/en not_active Abandoned
- 2003-12-01 EA EA200500738A patent/EA200500738A1/ru unknown
- 2003-12-01 CN CNA200380105166XA patent/CN1720248A/zh active Pending
- 2003-12-01 OA OA1200500173A patent/OA12968A/en unknown
- 2003-12-01 HR HR20050494A patent/HRP20050494A2/hr not_active Application Discontinuation
- 2003-12-04 AR ARP030104471A patent/AR042295A1/es unknown
- 2003-12-05 TW TW092134360A patent/TW200427691A/zh unknown
2004
- 2004-10-08 US US10/962,071 patent/US20050165047A1/en not_active Abandoned
2005
- 2005-05-12 IS IS7844A patent/IS7844A/is unknown
- 2005-05-17 ZA ZA200503988A patent/ZA200503988B/en unknown
- 2005-05-26 NO NO20052560A patent/NO20052560L/no not_active Application Discontinuation
- 2005-06-03 EC EC2005005834A patent/ECSP055834A/es unknown
- 2005-06-06 MA MA28315A patent/MA27604A1/fr unknown
- 2005-06-06 CR CR7859A patent/CR7859A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200427691A (en)	2004-12-16
BR0317019A (pt)	2005-10-25
CN1720248A (zh)	2006-01-11
NO20052560D0 (no)	2005-05-26
US20050165047A1 (en)	2005-07-28
CR7859A (es)	2005-07-08
NO20052560L (no)	2005-08-17
AU2003302911A1 (en)	2004-06-30
MXPA05005943A (es)	2005-08-18
JP2006510664A (ja)	2006-03-30
IS7844A (is)	2005-05-12
KR20050087826A (ko)	2005-08-31
WO2004052894A1 (en)	2004-06-24
CA2506529A1 (en)	2004-06-24
EP1572700A1 (en)	2005-09-14
AR042295A1 (es)	2005-06-15
MA27604A1 (fr)	2005-11-01
HRP20050494A2 (en)	2005-10-31
PL377052A1 (pl)	2006-01-23
EA200500738A1 (ru)	2005-12-29
ZA200503988B (en)	2006-09-27
ECSP055834A (es)	2005-08-11

Publication	Publication Date	Title
US7067515B2 (en)	2006-06-27	Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
US6828330B2 (en)	2004-12-07	Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6911543B2 (en)	2005-06-28	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7001900B2 (en)	2006-02-21	Azabicyclic compounds for the treatment of disease
US20030105089A1 (en)	2003-06-05	Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
US6562816B2 (en)	2003-05-13	Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
US20020052389A1 (en)	2002-05-02	Quinuclidine-substituted aryl compounds for treatment of disease
US6849620B2 (en)	2005-02-01	N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US20040147522A1 (en)	2004-07-29	Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
US7176198B2 (en)	2007-02-13	1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
US20050165047A1 (en)	2005-07-28	Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
CA2455773A1 (en)	2003-03-06	Substituted-aryl 7-aza¬2.2.1\|bicycloheptanes for the treatment of disease
US20050059698A1 (en)	2005-03-17	Quinuclidines-substituted-multi-cyclic-heteroaryls for treatment of disease
HK1081951A (en)	2006-05-26	Crystalline fumarate salts of 1-azabicyclo[2,2,2]oct substituted furo[2,3-c]pyridinyl carboxamide and compostions and preparations thereof
AU2002348498A1 (en)	2002-12-23	Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease